title: Challenges and recommendations for early identification of metastatic disease in prostate cancer.
abstract: Prostate cancer is often associated with metastases to bone and/or soft tissue. The progression to metastatic castrate-resistant prostate cancer is a seminal event in disease progression affecting treatment decisions. A multidisciplinary group was convened to review the currently available imaging guidelines for metastatic disease in prostate cancer and found no consensus on eligibility criteria, type of imaging modality, and the frequency of scanning for detecting metastatic disease. The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer.
authors.affiliation: University of Colorado, Denver-Aurora, CO. Electronic address: edc@edavidcrawford.com.
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
authors.affiliation: Icahn School of Medicine at Mount Sinai, New York, NY.
authors.forename: Nelson N
authors.initials: NN
authors.lastname: Stone
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA.
authors.forename: Evan Y
authors.initials: EY
authors.lastname: Yu
authors.affiliation: University of Colorado School of Medicine, Denver, CO.
authors.forename: Phillip J
authors.initials: PJ
authors.lastname: Koo
authors.affiliation: Durham VA and Duke University, Durham, NC.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Freedland
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY.
authors.forename: Susan F
authors.initials: SF
authors.lastname: Slovin
authors.affiliation: Thomas Jefferson University, Philadelphia, PA.
authors.forename: Leonard G
authors.initials: LG
authors.lastname: Gomella
authors.affiliation: Oncology Consortium, Scottsdale, AZ.
authors.forename: E Roy
authors.initials: ER
authors.lastname: Berger
authors.affiliation: Medical University of South Carolina, Charleston, SC.
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Keane
authors.affiliation: Lancaster Urology, Lancaster, PA.
authors.forename: Paul
authors.initials: P
authors.lastname: Sieber
authors.affiliation: Carolina Urologic Research Center, Myrtle Beach, SC.
authors.forename: Neal D
authors.initials: ND
authors.lastname: Shore
authors.affiliation: Yale University Cancer Center, New Haven, CT.
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Petrylak
mesh_terms: D001859:Bone Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000556:secondary; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D064847:Multimodal Imaging; D018579:Patient Selection; D049268:Positron-Emission Tomography; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology*; D012983:Soft Tissue Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000556:secondary; D014057:Tomography, X-Ray Computed
chemical_list: D017430:Prostate-Specific Antigen